Findings

What do systematic reviews say?

75 questions · 75 findings · 8 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 23 · 30.7%GRADE not reported 1 · 1.3%Very low 16 · 21.3%Low 24 · 32%Moderate 11 · 14.7%High 0 · 0%

Dornase alfa vs mannitol

FEV1 · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 0.02
231 participants
Low

Dornase alfa vs mannitol

FVC · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Low

Dornase alfa vs mannitol

QoL · children with cystic fibrosis

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 10.61 [0.27, 20.95]
231 participants
Low

Dornase alfa vs mannitol

Exacerbations · children with cystic fibrosis

Dornase alfa showed no clear difference in number of people experiencing exacerbations ‐ at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 1.1 [0.25, 4.84]
231 participants
Low

Dornase alfa vs dornase alfa and mannitol

FEV1 · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with dornase alfa and mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 0.1
231 participants
Low

Dornase alfa vs dornase alfa and mannitol

FVC · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with dornase alfa and mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 0.13
231 participants
Low

Dornase alfa vs dornase alfa and mannitol

QoL · children with cystic fibrosis

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with dornase alfa and mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 10.61 [0.27, 20.95]
231 participants
Low

Dornase alfa vs dornase alfa and mannitol

Exacerbations · children with cystic fibrosis

Dornase alfa showed no clear difference in number of people experiencing exacerbations at 3 months compared with dornase alfa and mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 0.55 [0.16, 1.92]
231 participants
Low

Intervention not reported

Death · Children aged 6‐60 months with cerebral malaria

The intervention may leads to lower death (low certainty).

1 finding from 1 review

Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
RR 0.81
1 study · 156 participants
Low

Intervention not reported

Major neurological sequelae · Children aged 6‐60 months with cerebral malaria

The review found no eligible studies for this question.

1 finding from 1 review

Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Coma recovery time · Children aged 6‐60 months with cerebral malaria

1 finding from 1 review

Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 156 participants
Low

Intervention not reported

Time to hospital discharge · Children aged 6‐60 months with cerebral malaria

The review found no eligible studies for this question.

1 finding from 1 review

Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Need for ventilation · Children aged 6‐60 months with cerebral malaria

The review found no eligible studies for this question.

1 finding from 1 review

Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Need for cardiopulmonary resuscitation · Children aged 6‐60 months with cerebral malaria

The review found no eligible studies for this question.

1 finding from 1 review

Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events · Children aged 6‐60 months with cerebral malaria

1 finding from 1 review

Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 156 participants
Low